Dr. Perrone's addition to XORTX's Clinical Advisory Board is...
Dr. Perrone's addition to XORTX's Clinical Advisory Board is viewed positively due to his extensive medical and professional experience, especially in ADPKD and kidney disease. His clinical research, trials, and regulatory agency work are anticipated to significantly contribute to XORTX's advanced clinical program and the XRX-OXY-201 registration trial.
Press Release: XORTX Announces New Clinical Advisory Board Member
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment